Could a cancer drug help beat malaria? new trial aims to find out

NCT ID NCT07559370

First seen May 05, 2026 · Last updated May 08, 2026 · Updated 1 time

Summary

This study tests whether adding imatinib (a drug used for certain cancers) to the standard malaria treatment can clear the parasite faster and help stop drug resistance. About 1,100 adults with mild to moderate malaria will receive either the standard 3-day treatment or a shorter 2-day combo. The goal is to see if the combo is safe, works faster, and reduces the chance of the infection coming back.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MALARIA (PLASMODIUM FALCIPARUM) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Victoria Biomedical Research Institute

    RECRUITING

    Kisumu, 40100, Kenya

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact

    Contact

    Contact

Conditions

Explore the condition pages connected to this study.